nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—Appetite absent—Octreotide—thymus cancer	0.0993	0.136	CcSEcCtD
Methazolamide—Tingling sensation—Octreotide—thymus cancer	0.0615	0.0842	CcSEcCtD
Methazolamide—Nephrolithiasis—Octreotide—thymus cancer	0.0615	0.0842	CcSEcCtD
Methazolamide—Urine output increased—Octreotide—thymus cancer	0.0447	0.0612	CcSEcCtD
Methazolamide—Polyuria—Octreotide—thymus cancer	0.0408	0.056	CcSEcCtD
Methazolamide—Drowsiness—Octreotide—thymus cancer	0.0276	0.0379	CcSEcCtD
Methazolamide—Haematuria—Octreotide—thymus cancer	0.0264	0.0361	CcSEcCtD
Methazolamide—Tinnitus—Octreotide—thymus cancer	0.0231	0.0317	CcSEcCtD
Methazolamide—Ill-defined disorder—Octreotide—thymus cancer	0.02	0.0275	CcSEcCtD
Methazolamide—Malaise—Octreotide—thymus cancer	0.0195	0.0267	CcSEcCtD
Methazolamide—Vertigo—Octreotide—thymus cancer	0.0194	0.0266	CcSEcCtD
Methazolamide—Convulsion—Octreotide—thymus cancer	0.0187	0.0256	CcSEcCtD
Methazolamide—Discomfort—Octreotide—thymus cancer	0.0182	0.0249	CcSEcCtD
Methazolamide—Anaphylactic shock—Octreotide—thymus cancer	0.0176	0.0241	CcSEcCtD
Methazolamide—Anorexia—Octreotide—thymus cancer	0.0168	0.023	CcSEcCtD
Methazolamide—Paraesthesia—Octreotide—thymus cancer	0.0158	0.0217	CcSEcCtD
Methazolamide—Somnolence—Octreotide—thymus cancer	0.0157	0.0215	CcSEcCtD
Methazolamide—Dyspepsia—Octreotide—thymus cancer	0.0155	0.0213	CcSEcCtD
Methazolamide—Decreased appetite—Octreotide—thymus cancer	0.0153	0.021	CcSEcCtD
Methazolamide—CA14—cardiac atrium—thymus cancer	0.0153	0.0566	CbGeAlD
Methazolamide—Gastrointestinal disorder—Octreotide—thymus cancer	0.0152	0.0208	CcSEcCtD
Methazolamide—Fatigue—Octreotide—thymus cancer	0.0152	0.0208	CcSEcCtD
Methazolamide—Feeling abnormal—Octreotide—thymus cancer	0.0145	0.0199	CcSEcCtD
Methazolamide—CA5B—hematopoietic system—thymus cancer	0.0141	0.0522	CbGeAlD
Methazolamide—Urticaria—Octreotide—thymus cancer	0.014	0.0192	CcSEcCtD
Methazolamide—Body temperature increased—Octreotide—thymus cancer	0.0139	0.0191	CcSEcCtD
Methazolamide—CA4—neck—thymus cancer	0.0131	0.0484	CbGeAlD
Methazolamide—Asthenia—Octreotide—thymus cancer	0.0126	0.0173	CcSEcCtD
Methazolamide—CA1—hematopoietic system—thymus cancer	0.0124	0.0461	CbGeAlD
Methazolamide—Diarrhoea—Octreotide—thymus cancer	0.0121	0.0165	CcSEcCtD
Methazolamide—Vomiting—Octreotide—thymus cancer	0.0112	0.0154	CcSEcCtD
Methazolamide—Rash—Octreotide—thymus cancer	0.0111	0.0152	CcSEcCtD
Methazolamide—Dermatitis—Octreotide—thymus cancer	0.0111	0.0152	CcSEcCtD
Methazolamide—Headache—Octreotide—thymus cancer	0.011	0.0151	CcSEcCtD
Methazolamide—CA2—neck—thymus cancer	0.0108	0.0401	CbGeAlD
Methazolamide—CA5B—cardiac atrium—thymus cancer	0.0107	0.0396	CbGeAlD
Methazolamide—Nausea—Octreotide—thymus cancer	0.0105	0.0143	CcSEcCtD
Methazolamide—CA12—lung—thymus cancer	0.00912	0.0338	CbGeAlD
Methazolamide—CA5B—thyroid gland—thymus cancer	0.00901	0.0334	CbGeAlD
Methazolamide—CYP2C19—hematopoietic system—thymus cancer	0.0088	0.0326	CbGeAlD
Methazolamide—CA1—lymphoid tissue—thymus cancer	0.00876	0.0324	CbGeAlD
Methazolamide—CA5B—lung—thymus cancer	0.00818	0.0303	CbGeAlD
Methazolamide—CA2—hematopoietic system—thymus cancer	0.00806	0.0299	CbGeAlD
Methazolamide—CA1—bone marrow—thymus cancer	0.00798	0.0295	CbGeAlD
Methazolamide—CA4—cardiac atrium—thymus cancer	0.00738	0.0273	CbGeAlD
Methazolamide—CA2—epithelium—thymus cancer	0.00737	0.0273	CbGeAlD
Methazolamide—CA1—lung—thymus cancer	0.00723	0.0268	CbGeAlD
Methazolamide—CA4—pituitary gland—thymus cancer	0.00721	0.0267	CbGeAlD
Methazolamide—CYP2C9—hematopoietic system—thymus cancer	0.00682	0.0253	CbGeAlD
Methazolamide—CYP2E1—hematopoietic system—thymus cancer	0.00646	0.0239	CbGeAlD
Methazolamide—CA4—bone marrow—thymus cancer	0.00623	0.0231	CbGeAlD
Methazolamide—CA4—thyroid gland—thymus cancer	0.00622	0.023	CbGeAlD
Methazolamide—CA2—cardiac atrium—thymus cancer	0.00612	0.0227	CbGeAlD
Methazolamide—CA2—pituitary gland—thymus cancer	0.00598	0.0221	CbGeAlD
Methazolamide—CA2—lymphoid tissue—thymus cancer	0.00568	0.021	CbGeAlD
Methazolamide—CA4—lung—thymus cancer	0.00565	0.0209	CbGeAlD
Methazolamide—CA5B—lymph node—thymus cancer	0.0056	0.0207	CbGeAlD
Methazolamide—CYP3A4—hematopoietic system—thymus cancer	0.0052	0.0193	CbGeAlD
Methazolamide—CA2—bone marrow—thymus cancer	0.00517	0.0191	CbGeAlD
Methazolamide—CA2—thyroid gland—thymus cancer	0.00516	0.0191	CbGeAlD
Methazolamide—CYP2D6—hematopoietic system—thymus cancer	0.00512	0.019	CbGeAlD
Methazolamide—CA1—lymph node—thymus cancer	0.00494	0.0183	CbGeAlD
Methazolamide—CA2—lung—thymus cancer	0.00468	0.0173	CbGeAlD
Methazolamide—CYP2E1—lymphoid tissue—thymus cancer	0.00455	0.0169	CbGeAlD
Methazolamide—CYP2E1—thyroid gland—thymus cancer	0.00413	0.0153	CbGeAlD
Methazolamide—CA4—lymph node—thymus cancer	0.00386	0.0143	CbGeAlD
Methazolamide—CYP2E1—lung—thymus cancer	0.00375	0.0139	CbGeAlD
Methazolamide—CA2—lymph node—thymus cancer	0.0032	0.0119	CbGeAlD
